Table 1.
Author | Study description | Treatment | Patient population | % 1L | % 2L | % 3L+ | N‡ | ORR‡ % | DOR, months | PFS, months | OS, months | % TNBC patients |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NCCN-recommended (v1.2016) monotherapies | ||||||||||||
Aftimos et al. [23] | Retrospective phase III sub-group analysis | Eri | 2L+ MBC w/mTNBC | 0 | 100 | 22 | 18 | N/R | N/R | N/R | 17 | |
Awada et al. [24] | Phase II | Pac | 1L mTNBC | 100 | 0 | 0 | 28 | 28.6 | N/R | 3.5 | 13.1 | 100 |
Baselga et al. [25] | Phase II | Cis | 1L–2L mTNBC | 72 | 28 | 0 | 60 | 10 | N/R | 1.5 | 9.4 | 100 |
Phase II | Cis | 1L mTNBC | 42 | 12 | N/R | N/R | N/R | 100 | ||||
Phase II | Cis | 2L mTNBC | 16 | 6 | N/R | N/R | N/R | 100 | ||||
Brufsky et al. [26] | RIBBON-2 | Physician’s choice chemo | 2L MBC w/mTNBC | 0 | 100 | 0 | 47 | 18 | N/R | 2.7 | 12.6 | 21 |
Isakoff et al. [27] | Phase II | Car/cis | 1L–2L mTNBC | 80 | 20 | 0 | 86 | 25.6 | N/R | 2.9 | 11 | 100 |
Phase II | Car/cis | 1L mTNBC | 69 | 29 | N/R | N/R | N/R | 100 | ||||
Phase II | Car/cis | 2L mTNBC | 17 | 11.8 | N/R | N/R | N/R | 100 | ||||
Miles et al. [28] | RIBBON-1 + AVADO + E2100 pooled subgroup | Cap/doc/pac | 1L MBC w/mTNBC | 100 | 0 | 0 | 255 | 23.3 | N/R | 5.4 | 17.5 | 26 |
Perez et al. [29] | BEACON | Physician’s choice chemo | 3L+ MBC w/mTNBC | 0 | 0 | 100 | 117 | N/R | N/R | N/R | 8.8 | 28 |
Pivot et al. [30] | Prespecified phase III subgroup | Cap | 1L–3L+ MBC w/mTNBC | 9 | 49 | 43 | 96 | 9 | N/R | 2.1 | N/R | 25 |
Sparano et al. [31] | Phase III | Cap | 1L–3L+ MBC w/mTNBC | 19 | 63 | 18 | 134 | N/R | N/R | 1.81 | N/R | 22 |
Study 301† | Phase III subgroup | Cap | 1L MBC w/mTNBC | 40 | 12 | 4.4 | N/R | 9.9 | 24.5 | |||
Eri | 1L MBC w/mTNBC | 40 | 10.4 | 6.6 | N/R | 13.1 | 27.1 | |||||
Phase III subgroup | Cap | 2L+ MBC w/mTNBC | 96 | ~ 10 | 5.9 | 2.8 | 9.2 | 24.5 | ||||
Eri | 2L+ MBC w/mTNBC | 110 | ~ 10 | 4.2 | 3.4 | 15.2 | 27.1 | |||||
Tredan et al. [32] | Phase II | Ixa | 1L mTNBC | 100 | 0 | 0 | 40 | 30 | 4.5 | 4.1 | N/R | 100 |
Twelves et al. [9] and Pivot et al. [13] | EMBRACE + 301 pooled subgroup | Eri | 1L–3L+ MBC w/mTNBC | 11 | 27 | 62 | 243 | 12 | N/R | 2.8 | 12.9 | 22.9 |
EMBRACE + 301 pooled subgroup | Eri | 2L+ MBC w/mTNBC | 199 | 11 | N/R | 2.8 | 12.4 | 22.9 | ||||
Twelves et al. [9] and Pivot et al. [13] | EMBRACE + 301 pooled subgroup | Physician’s choice chemo | 1L–3L+ MBC w/mTNBC | 13 | 37 | 50 | 185 | 10.3 | N/R | 2.6 | 8.2 | 23.1 |
EMBRACE + 301 pooled subgroup | Physician’s choice chemo | 2L+ MBC w/mTNBC | 153 | 9 | N/R | 2.5 | 8.1 | 23.1 | ||||
von Minckwitz et al. [33] | TANIA | Physician’s choice chemo | 2L MBC w/mTNBC | 0 | 100 | 0 | 57 | N/R | N/R | 2.1 | N/R | 23 |
NCCN-v1.2016-recommended combination therapies | ||||||||||||
Brodowicz et al. [34]§ | TURANDOT | Bev+pac | 1L MBC w/mTNBC | 100 | 0 | 0 | 63 | 49 | N/R | 9 | 24.2 | 22 |
Dieras et al. [35] | Phase II | Bev+pac | 1L–2L mTNBC | 81 | 19 | 0 | 61 | 47.53 | 7.5 | 7.2 | 17.4 | 100 |
Phase II | Bev+pac | 1L mTNBC | 46 | N/R | N/R | 7.2 | N/R | 100 | ||||
Phase II | Bev+pac | 2L mTNBC | 16 | N/R | N/R | 7 | N/R | 100 | ||||
Fan et al. [36] | Phase II | Doc+cap | 1L mTNBC | 100 | 0 | 0 | 26 | 15.4 | N/R | 4.8 | 21.5 | 100 |
Halim et al. [37] | Phase II | Car+pac | 2L+ mTNBC | 0 | 100 | 50 | 60 | N/R | N/R | N/R | 100 | |
Li et al. [38] | Phase II | Cap+cis | 1L–3L mTNBC | 84.9 | 12.1 | 3 | 33 | 63.6 | N/R | 8.2 | 17.8 | 100 |
Phase II | Cap+cis | 1L mTNBC | 28 | 64.3 | N/R | 8.2 | 19.6 | 100 | ||||
Phase II | Cap+cis | 2L–3L mTNBC | 5 | 60 | N/R | 5.1 | 16.5 | 100 | ||||
Liao et al. [39] | Phase II | Doc+cap | 1L mTNBC | 100 | 0 | 0 | 27 | 14.8 | N/R | 4.9 | 21.5 | 100 |
Liao et al. [39] | Phase II | Vin+cap | 1L mTNBC | 100 | 0 | 0 | 18 | 27.8 | N/R | 5.2 | 18.2 | 100 |
Miles et al. [28]* (many combinations with high ORR—OS is still not much higher) | Pooled phase III (E2100, AVADO, RIBBON-1) | Bev+(cap/doc/pac/nab-pac/(dox/epi/CP/ FU)) | 1L MBC w/mTNBC | 100 | 0 | 0 | 360 | 42.3 | N/R | 8.1 | 18.9 | 25 |
O’Shaughnessy et al. [40] | Phase III | Gem+car | 1L–3L mTNBC | 58 | 42 | 244 | 32 | N/R | 4.1 | 11.1 | 100 | |
Phase III | Gem+car | 1L mTNBC | 149 | N/R | N/R | 4.6 | 13.9 | 100 | ||||
Phase III | Gem+car | 2L–3L mTNBC | 109 | N/R | N/R | 2.9 | 8.1 | 100 | ||||
Pivot et al. [30] | Prespecified phase III subgroup | Ixa+cap | 1L–3L+ MBC w/mTNBC | 7 | 48 | 45 | 91 | 27 | N/R | 4.1 | N/R | 24.3 |
Rugo et al. [41] | Phase III | Bev+nab-pac | 1L MBC w/mTNBC | 100 | 0 | 0 | 65 | N/R | N/R | 7.4 | N/R | 24 |
Rugo et al. [41] | Phase III | Bev+ixa | 1L MBC w/mTNBC | 100 | 0 | 0 | 63 | N/R | N/R | 5.6 | N/R | 26 |
Rugo et al. [41] | Phase III | Bev+pac | 1L MBC w/mTNBC | 100 | 0 | 0 | 73 | N/R | N/R | 6.5 | N/R | 26 |
Sparano et al. [31] | Phase III | Ixa+cap | 1L–3L+ MBC w/mTNBC | 20 | 61 | 19 | 122 | N/R | N/R | 4.2 | N/R | 20 |
1L first-line, 2L second-line, 3L third-line, APaT all patients as treated, Bev bevacizumab, Cap capecitabine, Car carboplatin, chemo chemotherapy, Cis cisplatin, CP cyclophosphamide, Doc docetaxel, Dox doxorubicin, Epi epirubicin, Eri eribulin, FU fluorouracil, Gem gemcitabine, Ixa ixabepilone, MBC metastatic breast cancer, mTNBC metastatic triple-negative breast cancer, N/R not reported, ORR objective response rate, Pac paclitaxel, TNBC triple-negative breast cancer, Vin vinorelbine
*Paclitaxel in E2100, docetaxel in AVADO, capecitabine in one cohort of RIBBON-1, and either a single-agent taxane or an anthracycline-based combination in the second cohort of RIBBON-1. Of the total n = 255 in the meta-analysis, n = 46 belong to the taxane/anthracycline cohort of RIBBON-1; the number (< 46) of this subset of patients receiving anthracycline combination is unknown
†Based on internal communication with trial sponsor (Eisai); not published results
‡n and ORR based on APaT population
§2L+ MBC with mTNBC outcomes are available in a separate study from Pivot et al. [13]